Screener
Mirum Pharmaceuticals, Inc. MIRM Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Amortized Cost | Unrealized Gain | Unrealized Loss | Estimated Fair Value |
|---|---|---|---|---|
| U.S. government bonds | 73,414 | 1 | (142) | 73,273 |
| Agency bonds | 16,500 | — | (69) | 16,431 |
| Commercial paper | 17,970 | — | — | 17,970 |
| Total cash equivalents and investments | $493,743 | $6 | $(472) | $493,277 |
| Classified as: | ||||
| Cash equivalents | $262,684 | |||
| Short-term investments | 107,563 | |||
| Long-term investments | 123,030 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s cumulative cost basis?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cumulative cost basis of $493.74M in Q2 2026.
- What does cumulative cost basis mean?
- The aggregate historical cost basis of assets or liabilities before adjustments for fair value, impairment, or amortization.
Ask your AI about Mirum Pharmaceuticals, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude